Literature DB >> 24733806

Interpreting plasma estrogen levels in breast cancer: caution needed.

Elizabeth J Folkerd1, Per E Lønning, Mitch Dowsett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24733806     DOI： 10.1200/JCO.2013.53.9411

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  11 in total

1.  Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.

Authors:  Meritxell Bellet; Kathryn P Gray; Prudence A Francis; István Láng; Eva Ciruelos; Ana Lluch; Miguel Angel Climent; Gustavo Catalán; Antoni Avella; Uriel Bohn; Antonio González-Martin; Roser Ferrer; Roberto Catalán; Analía Azaro; Agnita Rajasekaran; Josefa Morales; Josep Vázquez; Gini F Fleming; Karen N Price; Meredith M Regan
Journal:  J Clin Oncol       Date:  2016-01-04       Impact factor: 44.544

2.  Systemic Levels of Estrogens and PGE2 Synthesis in Relation to Postmenopausal Breast Cancer Risk.

Authors:  Sangmi Kim; Jeff Campbell; Wonsuk Yoo; Jack A Taylor; Dale P Sandler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-11-18       Impact factor: 4.254

3.  Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.

Authors:  Jason D Robarge; Zereunesay Desta; Anne T Nguyen; Lang Li; Daniel Hertz; James M Rae; Daniel F Hayes; Anna M Storniolo; Vered Stearns; David A Flockhart; Todd C Skaar; N Lynn Henry
Journal:  Breast Cancer Res Treat       Date:  2016-12-09       Impact factor: 4.872

4.  Modeling estrogen receptor-positive breast cancers in mice: is it the best we can do?

Authors:  Ioulia Chatzistamou; Hippokratis Kiaris
Journal:  Endocr Relat Cancer       Date:  2016-09-12       Impact factor: 5.678

Review 5.  Mammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies.

Authors:  Michael S Shawky; Hilary Martin; Honor J Hugo; Thomas Lloyd; Kara L Britt; Andrew Redfern; Erik W Thompson
Journal:  Oncotarget       Date:  2017-01-17

6.  The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients.

Authors:  Ingeborg J H Vriens; Ashley J R De Bie; Maureen J B Aarts; Maaike de Boer; Irene E G van Hellemond; Joyce H E Roijen; Ron J T van Golde; Adri C Voogd; Vivianne C G Tjan-Heijnen
Journal:  Oncotarget       Date:  2017-02-14

7.  Curcumin for the Prevention of Epithelial-Mesenchymal Transition in Endoxifen-Treated MCF-7 Breast Cancer Cel

Authors:  P Paramita; Bantari WK Wardhani; Septelia Inawati Wanandi; Melva Louisa
Journal:  Asian Pac J Cancer Prev       Date:  2018-05-26

8.  Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.

Authors:  Irene E G van Hellemond; Ingeborg J H Vriens; Petronella G M Peer; Astrid C P Swinkels; Carolien H Smorenburg; Caroline M Seynaeve; Maurice J C van der Sangen; Judith R Kroep; Hiltje de Graaf; Aafke H Honkoop; Frans L G Erdkamp; Franchette W P J van den Berkmortel; Maaike de Boer; Wilfred K de Roos; Sabine C Linn; Alexander L T Imholz; Vivianne C G Tjan-Heijnen
Journal:  Int J Cancer       Date:  2019-01-16       Impact factor: 7.396

9.  An Ultrasensitive Routine LC-MS/MS Method for Estradiol and Estrone in the Clinically Relevant Sub-Picomolar Range.

Authors:  Bjørn-Erik Bertelsen; Ralf Kellmann; Kristin Viste; Anne Turid Bjørnevik; Hans Petter Eikesdal; Per Eystein Lønning; Jørn V Sagen; Bjørg Almås
Journal:  J Endocr Soc       Date:  2020-04-21

10.  Cytochrome P450 1A2 Metabolizes 17β-Estradiol to Suppress Hepatocellular Carcinoma.

Authors:  Jianwai Ren; George G Chen; Yi Liu; Xianwei Su; Baoguang Hu; Billy C S Leung; Y Wang; Rocky L K Ho; Shengli Yang; Gang Lu; C G Lee; Paul B S Lai
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.